Centro Oncológico y Tratamiento Oncología - CDIEM
Centro Oncológico y Tratamiento Oncología - CDIEM
María Luisa Santander 485, 7500859 Providencia, Región Metropolitana, Chile
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Ricardo Silva
Open studies
Lung cancer
Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC - MB12-C-01-22 - Laboratorio Elea Phoenix S.A.See more
A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer - Be6A Lung-01 - Seagen Inc.See more
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer - MARYGOLD - AmgenSee more
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) - Eucalyptus - AmgenSee more
Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors - STELLAR-002 - ExelixisSee more
Head and neck cancer
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients - MCLA-158-CL02 - Merus N.V.See more
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) - MCLA-158-CL03 - Merus N.V.See more
Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors - STELLAR-002 - ExelixisSee more
Bile Duct Cancer
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer - JZP598-302 - Jazz PharmaceuticalsSee more
Kidney cancer
Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors - STELLAR-002 - ExelixisSee more
Liver Cancer
Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors - STELLAR-002 - ExelixisSee more
Prostate cancer
Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors - STELLAR-002 - ExelixisSee more
Skin cancer
Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy® - CJPB898A12301 - SandozSee more
Solid tumors
Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors - STELLAR-002 - ExelixisSee more
Urothelial cancer
Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors - STELLAR-002 - ExelixisSee more
